executive committee

A/Prof. Herbert Loong

The Chinese University of Hong Kong, Hong Kong

A/Prof. Herbert H. Loong holds conjoint appointments of Clinical Associate Professor in the Department of Clinical Oncology and Deputy Medical Director of the Phase 1 Clinical Trials Centre of The Chinese University of Hong Kong. He is also the current and founding convenor of the Prince of Wales Hospital Adult Sarcoma Multidisciplinary Team.

A/Prof. Loong was a recipient of the European Cancer Congress Fellowship Grant (2013), the American Society of Clinical Oncology (ASCO) Annual Meeting Merit Award (2014), and the Hong Kong College of Physicians Young Investigators’ Award (2014). Nominated by patients and their caregivers, A/Prof. Loong led the Lung Cancer Team at CUHK to be bestowed the IASLC Foundation Cancer Care Team Award in recognition for providing the best thoracic oncology care in “Asia & Rest of the World” in 2018.

He has served or continues to serve in various capacities in various professional international oncology bodies, including the International Affairs Committee and the Asia-Pacific Regional Council of ASCO, the Membership, Education and Communications Committees of the IASLC. He has been elected as a Board Member of the Connective Tissue Oncology Society (CTOS) for 2022-2024. In his appointment as a Registration Committee member of Pharmacy and Poisons Board of Hong Kong, he helps oversee the registration of medicinal products and clinical trials in the territory.
read more

Prof. Daniel Tan

National Cancer Centre Singapore, Singapore

Prof. Daniel Tan holds positions as a Senior Consultant, Head of Department of Clinical Trials and Epidemiological Sciences at National Cancer Centre Singapore (NCCS), Associate Professor at Duke-NUS Medical School, and Senior Clinician-Scientist at Genome Institute of Singapore. He is also leading the Experimental Cancer Therapeutics Unit (ECRU) at NCCS, and has been instrumental to growing it to one of the largest Phase I units in Asia, running up to 30 – 40 trials at any one time. Additionally, he is the Principal Investigator of the Cancer Therapeutics Research Laboratory at NCCS focused on developing representative patient-derived pre-clinical models to gain insights to drug response and resistance, complementing his role as the Principal Investigator for multiple biomarker-driven early phase clinical trials. He also chairs Asian Thoracic Oncology Research Group (ATORG), which is a central coordinating platform for multi-centre translational research and clinical trials on thoracic malignancies in Asia Pacific.

Prof. Tan’s main area of interest is in thoracic, head and neck malignancies and drug development. His research includes application of “omics” technologies to unravel drug resistance in cancer therapeutics and accelerate the development of novel agents and biomarkers. His research has been recognised through multiple local and international awards, including European Society of Medical Oncology Congress Travel Award, American Society of Clinical Oncology (ASCO) Merit Awards and ASCO Young Investigator Award. He has been active in developing educational resources to enhance quality of lung cancer care globally and is currently involved in The Lancet Commission on Lung Cancer.
read more

Prof. Toshio Shimizu

KMU, Kansai Medical University Hospital, Osaka Japan, Japan

Prof. Toshio Shimizu is Professor, Department of New Experimental Therapeutics and Director of Early Phase 1 Drug Development Service at Kansai Medical University Hospital, Osaka Japan. Prof. Shimizu's research interests are specially focusing on the oncology early phase 1 drug development and medical oncology. He had performed an advanced clinical fellowship in early phase 1 drug development at START (South Texas Accelerated Research Therapeutics) in San Antonio, TX, United States during 2010-2012 supervised by Anthony W. Tolcher, M.D., FRCPC. Prof. Shimizu is currently the principal investigator of early phase 1 clinical trials of novel anti-cancer agents for patients with advanced cancers and he has launched new oncology global first-in-human (FIH) phase 1 trials platform at Kansai Medical University Hospital since November 2024. From 2026, Prof. Shimizu has also been cross appointed as the Director of NEXT Oncology KMU JAPAN, as the part of one of the world’s largest phase 1 cancer trial organizations under NEXT Oncology USA and IQVIA group.

He has been a Joint Scientific Committee Review (External IRB) Member in The Consortium on Harmonization of Institutional Requirements for Clinical Research (CHAIR), serving as a scientific reviewer for Phase 1 trials in Hong Kong, HKSAR China. He has also been appointed as scientific committee and faculty member of ESMO TAT (Targeted Anticancer Therapies) since 2022 as well as executive committee of Asia Pacific Oncology Drug Development Consortium (APODDC). Additionally, Prof. Shimizu has authored and co-authored over 100 peer-reviewed publications of original cancer research in internationally respected scientific journals.
read more
scientific committee

  • Dr. Amy Prawira

    Prince of Wales Hospital Sydney
    Australia

  • A/Prof. Ben Tran

    Peter MacCallum Cancer Centre
    Australia

  • Dr. Daphne Day

    Monash Health/ Monash University
    Australia

  • Dr. Mun Hui

    Chris O'Brien Lifehouse
    Australia

  • A/Prof. Herbert Loong

    The Chinese University of Hong Kong
    Hong Kong

  • Dr. Joanne Chiu

    The University of Hong Kong
    Hong Kong

  • A/Prof. Takafumi Koyama

    National Cancer Center Hospital
    Japan

  • Prof. Toshio Shimizu

    KMU, Kansai Medical University Hospital, Osaka Japan
    Japan

  • Dr. Sehhoon Park

    Samsung Medical Center
    Korea

  • Dr. Pei Jye Voon

    Hospital Umum Sarawak
    Malaysia

  • Dr. Michelle Wilson

    Auckland City Hospital
    New Zealand

  • Dr. Frederic Ivan Ting

    Riverside Bacolod Cancer Care Center
    Philippines

  • Prof. Daniel Tan

    National Cancer Centre Singapore
    Singapore

  • A/Prof. David Tan

    National University Hospital
    Singapore

  • Dr. Tira Tan

    National Cancer Centre Singapore
    Singapore

  • Dr. Valerie Heong

    Tan Tock Seng Hospital
    Singapore

  • Prof. Chia-Chi (Josh) Lin

    National Taiwan University Hospital
    Taiwan

  • A/Prof. Naiyarat Prasongsook

    Phramongkutklao Hospital
    Thailand

  • Prof. Thanyanan Baisamut (Reungwetwattana)

    Faculty of Medicine Ramathibodi Hospital, Mahidol University
    Thailand

  • Prof. Naoto T. Ueno

    University of Hawai'i Cancer Center (UHCC)
    United States

  • Prof. Aya El. Helali

    Queen Mary Hospital
    Hong Kong

Copyright © 2022 Asia Pacific Oncology Drug Development Consortium (APODDC) | Website Designed By Elves Lab | Privacy
//